Holostem
Holostem is an Italian biotech company developing, producing, and distributing Advanced Therapy Medicinal Products based on epithelial stem cells, commercially marketing Holoclar (the first approved stem-cell therapy for Limbal Stem Cell Deficiency) and advancing gene therapies for Epidermolysis Bullosa across European treatment centers.
- Company typePrivate
- Founded2008
- HeadquartersNovi Di Modena, Italy
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Holostem does
Holostem S.r.l. a Socio Unico is an Italian biotechnology company founded in 2008 as a spin-off of the University of Modena and Reggio Emilia (Unimore), with investment from Chiesi Farmaceutici. The company develops, produces, registers, and distributes Advanced Therapy Medicinal Products (ATMPs) based on cultured epithelial stem cells, for both cell therapy and gene therapy indications. It is headquartered within the Centro di Medicina Rigenerativa Stefano Ferrari at Unimore in Modena, Italy, operates a GMP-certified manufacturing facility, and employs between 11 and 50 staff.
Holostem's commercial product is Holoclar, the first stem cell-based medicinal product formally approved in the Western world, consisting of ex-vivo reconstructed autologous human corneal epithelium used to treat moderate to severe Limbal Stem Cell Deficiency (LSCD) caused by ocular burns. Holoclar received conditional European marketing authorization in February 2015 and was upgraded to full authorization in 2024 in both the EU (Decision No. 1299/2024) and the UK (MHRA, March 2024). A US equivalent (GPLSCD01) holds FDA orphan drug designation. The pipeline includes Hologene 5, a Phase II/III combined cell and gene therapy for Junctional Epidermolysis Bullosa using transgenic keratinocytes carrying the LAMB3 gene. Long-term clinical evidence spans 223 patients and 10+ years of follow-up, with success rates of 51-77%.
Holostem's go-to-market is a specialized enterprise field-sales model: Holoclar is distributed directly from the Modena GMP facility to authorized treatment centers across ~20 sites in 10+ European countries, with EMA-mandated surgeon training and 36-hour shelf-life logistics. In Italy, only two centers (San Raffaele Milano and San Giovanni Addolorata Roma) are currently authorized; the UK is served via a Newcastle Hospitals NHS partnership, and the Czech Republic via Medasol. In June 2022, the Board approved a transition from a for-profit S.r.l. to a nonprofit foundation, indicating a strategic shift toward patient access over profit maximization. The company retains Chiesi as a key strategic partner, though marketing authorization was transferred from Chiesi to Holostem in 2020.
Holostem firmographics
Firmographics- Name
- Holostem
- Legal name
- Holostem S.r.l. a Socio Unico
- Website
- https://holostem.com
- Company type
- Private
- Founded year
- 2008
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Holostem is an Italian biotech company developing, producing, and distributing Advanced Therapy Medicinal Products based on epithelial stem cells, commercially marketing Holoclar (the first approved stem-cell therapy for Limbal Stem Cell Deficiency) and advancing gene therapies for Epidermolysis Bullosa across European treatment centers.
- Ownership category
- akta.pro rank
Holostem industry classification
Industry- Product category
- Regenerative Medicine
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Stem Cell Therapies (MSC/iPSC/HSC-derived) (HLAAABAE)
Keywords
Where Holostem is headquartered
LocationHeadquarters
- HQ city
- Novi Di Modena
- HQ country
- Italy
- HQ region
- Europe
Offices1 record
Markets served
Holostem business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales
Revenue model
- Pharmaceutical Product Sales (Holoclar): Holoclar is produced and distributed by Holostem, with Chiesi holding marketing authorization in Europe. The product is distributed to authorized treatment centers across European countries. Holoclar received full marketing authorization in EU and UK in 2024, transitioning from conditional status.
- Gene Therapy Development: Development of gene therapy products for Epidermolysis Bullosa (Hologene 5) and other genodermatoses. Revenue may come from clinical trial partnerships, regulatory approvals, and future commercialization.
- Foundation Model Transition: In June 2022, Holostem began transitioning from a for-profit company to a non-profit foundation, which may change the revenue model structure to focus on patient access rather than profit maximization.
Go-to-market motion1 record
Distribution channels4 records
Marketing channels8 records
Holostem product offering
Product offeringCore offering
Holostem develops, produces, registers, and distributes Advanced Therapy Medicinal Products (ATMPs) based on cultured epithelial stem cells for cell and gene therapy. Its lead commercial product, Holoclar, is the first stem cell-based medicinal product approved in the Western world (EU 2015, UK 2024), consisting of autologous cultivated corneal epithelium used to treat Limbal Stem Cell Deficiency from ocular burns. The company also develops gene therapies for Epidermolysis Bullosa using transgenic epidermal cultures.
Product overview
Holostem is a biotech company specializing in advanced therapy medicinal products (ATMPs) based on cultured epithelial stem cells for cell and gene therapy. The core product portfolio includes Holoclar (approved cell therapy for Limbal Stem Cell Deficiency), GPLSCD01 (US orphan drug designated equivalent), Hologene 5 (gene therapy for Epidermolysis Bullosa in clinical trials), cell therapy for corneal surface regeneration, and gene therapy for Epidermolysis Bullosa. All products utilize autologous stem cell approaches combined with gene therapy where applicable.
Differentiator
Problem solved
Functional benefit
Products and services
- Holoclar Advanced cell therapy medicinal product consisting of ex-vivo reconstructed autologous human corneal epithelium containing limbal stem cells, produced from a 1-2mm² biopsy of the patient's undamaged limbus and cultivated to form a graft that is transplanted onto the damaged eye. Used to treat moderate to severe Limbal Stem Cell Deficiency (LSCD) caused by physical or chemical eye burns in adult patients.
- GPLSCD01 Experimental cell therapy product (known as Holoclar in the EU) consisting of autologous expanded ex-vivo human corneal epithelial cells for the treatment of Limbal Stem Cell Deficiency. Developed for the US market where it has received FDA orphan drug designation but is not yet approved.
- Hologene 5 - Gene Therapy for Epidermolysis Bullosa Combined cell and gene therapy product for treatment of Junctional Epidermolysis Bullosa (JEB) caused by LAMB3 mutations. Uses transgenic keratinocytes and epidermal stem cells genetically corrected with gamma-retroviral vector carrying functional human LAMB3 cDNA to restore functional epidermis. Approximately 80% body surface area (about 1 square meter) successfully treated in the landmark patient case published in Nature (2017) with 5+ years stable transgenic epidermis confirmed in New England Journal of Medicine (2021).
Quantifiable outcome
- 77% success rate measured by ophthalmologists in HOLOCORE clinical study
- +4 more outcomes
Companies that use Holostem
Customer profileNamed customers6 records
Segments3 records
Ideal customer profiles1 record
Holostem technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Holostem partnerships and signals
Strategic signalPartnerships
Ten partnerships are on record, tiered core and supporting.
- Fondazione Banca degli Occhi del VenetocoreStrategic partnership to expand access to advanced therapies for ocular pathologies. The agreement includes strengthening the network of centers administering Holoclar, sharing expertise for medical training and research on stem cells applied to ophthalmology. This represents a virtuous example of public-private synergy with patients at the center.
- Newcastle Hospitals NHS Foundation TrustcorePartnership to make Holoclar available to patients at specialist centers across England. Newcastle pharmacists worked extensively with Holostem to overcome import challenges and develop regulatory authorizations. The partnership enabled NHS access through 4 approved treatment sites.
- Northern Alliance Advanced Therapies Treatment CentresupportingFacilitated the partnership between Newcastle Hospitals and Holostem, working to support the use of advanced therapies and ensure access for NHS patients.
- Azienda Ospedaliero-Universitaria di ModenacoreEstablished a PDTA (Percorso Diagnostico Terapeutico Assistenziale) for Epidermolysis Bullosa integrating over 30 specialties. The center is led by Prof. Cristina Magnoni and serves patients from across Italy. Prof. Michele De Luca's research group provides ongoing research contributions.
- Medasol (Bluedil International)supportingMedasol provides market access and commercial services for Holoclar in Czech Republic. With 20 years of experience commercializing orphan drugs, they support pharmaceutical and biotech companies in making innovative treatments available to patients with rare diseases.
- University Hospital Brno Eye CliniccoreHoloclar became available in Czech Republic through the University Hospital Brno Eye Clinic, founded in 1990. The clinic specializes in anterior segment microsurgery including corneal transplants, vitreoretinal surgery, ocular traumatology, and strabismus surgery.
- Le Ali di Camilla AssociationsupportingAssociation promoting research and care for Epidermolysis Bullosa in Modena. Collaborated in organizing the EB Hub presentation and supports the overall EB patient community and research network.
- EB HubcoreA unique center at Policlinico di Modena serving as a meeting point for diagnosis, research, care, and innovative therapies for Epidermolysis Bullosa. Involves collaboration between Azienda Ospedaliera, University, Holostem, and patient associations.
- Chiesi FarmaceuticicoreChiesi Farmaceutici holds the European marketing authorization for Holoclar granted by the European Commission in 2015. Chiesi invested in certifying the Centro di Medicina Rigenerativa GMP facility and supported the product's regulatory pathway. In June 2020, Holostem signed an agreement for transfer of Holoclar marketing rights from Chiesi to Holostem.
- University of Modena and Reggio Emilia (Unimore)coreHolostem is a university spin-off located within the Centro di Medicina Rigenerativa Stefano Ferrari at Unimore. Prof. Michele De Luca serves as Director of the Center and Scientific Director of Holostem. The collaboration enables transfer of research findings to clinical application and patient access to advanced therapies.
Scale indicators8 records
Recent moves8 records
Expansion highlights5 records
Holostem competitors and assessment
Company assessmentDirect peers
- Aurion Biotech: Aurion Biotech is developing allogeneic corneal endothelial cell therapies for corneal edema and endothelial dysfunction. It is the closest direct peer to Holostem because both companies operate in autologous/allogeneic corneal cell therapy, target ophthalmic indications of the anterior segment of the eye, and rely on GMP cell-manufacturing platforms.
- jCyte: jCyte develops human retinal progenitor cell therapies for retinal degenerative diseases including retinitis pigmentosa. It is comparable to Holostem as a clinical-stage cell therapy company focused on ophthalmology with autologous/semi-autologous cell therapy assets.
- GenSight Biologics: GenSight Biologics develops gene therapies for inherited retinal diseases and optic neuropathies. It is a direct peer because both companies are European-based, ophthalmology-focused advanced therapy developers combining cell or gene therapy approaches to address rare ocular indications.
Broad incumbents
- Regenxbio: Regenxbio develops AAV-based gene therapy platforms with applications across ophthalmology (e.g., RGX-314) and other rare diseases. It is comparable to Holostem because both develop advanced therapy medicinal products targeting rare ocular indications using gene-therapy delivery technology.
- Chiesi Farmaceutici: Chiesi is the strategic shareholder and former marketing-authorization holder for Holoclar and operates broadly in rare diseases, cell/gene therapy, and specialty pharma. It is comparable as the incumbent commercial partner and broader industry player supporting Holostem's commercialization rather than as a competing technology developer.
- Iovance Biotherapeutics: Iovance is a commercial-stage cell therapy company developing tumor-infiltrating lymphocyte (TIL) therapies for solid tumors. It is comparable as a large-scale autologous cell therapy developer with established GMP manufacturing capabilities for patient-derived cellular products.
Others
- Kala Pharmaceuticals: Kala Pharmaceuticals is a specialty ophthalmic drug delivery company developing therapies for front- and back-of-the-eye diseases. It is thematically adjacent rather than directly competitive — both companies operate in ophthalmology, but Kala's approach is small-molecule drug delivery rather than cell or gene therapy.
Emerging players
- Capricor Therapeutics: Capricor develops cell-derived extracellular vesicle and cell therapy products (e.g., CAP-1002) for Duchenne muscular dystrophy and other rare diseases. It is comparable as an emerging regenerative-medicine player addressing rare diseases with cell-based therapeutics.
- Adaptimmune: Adaptimmune develops engineered T-cell receptor (TCR-T) cell therapies for solid tumors. It is comparable as an emerging cell therapy company using patient-derived cellular products with gene-engineering steps, sharing Holostem's autologous + gene-modification platform approach.
- Lineage Cell Therapeutics: Lineage Cell Therapeutics develops allogeneic cell transplant therapies for neurological and ophthalmic indications, including OpRegen for dry age-related macular degeneration. It is comparable to Holostem because both companies operate cell therapy platforms targeting ophthalmic indications with regenerative mechanisms.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat6 records
Key risks6 records
Key highlights6 records
Customer concentration
Holostem social profiles
Digital presenceHolostem financial estimates
Financial estimateRevenue estimate
Valuation estimate
Holostem leadership team
Management profileNumber of profiles
Profiles5 records
Holostem funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Holostem M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Holostem
What does Holostem do?
Holostem develops, produces, registers, and distributes Advanced Therapy Medicinal Products (ATMPs) based on cultured epithelial stem cells for cell and gene therapy. Its lead commercial product, Holoclar, is the first stem cell-based medicinal product approved in the Western world (EU 2015, UK 2024), consisting of autologous cultivated corneal epithelium used to treat Limbal Stem Cell Deficiency from ocular burns. The company also develops gene therapies for Epidermolysis Bullosa using transgenic epidermal cultures.
Is Holostem a public or private company?
Holostem is a private company. It is classified as corporate owned and is currently operating.
When was Holostem founded?
Holostem was founded in 2008. It employs 51 to 100 people.
Where is Holostem based?
Holostem is headquartered in Novi Di Modena, Italy, in the Europe region.
How does Holostem make money?
Three revenue lines are on record. Pharmaceutical Product Sales (Holoclar) is the primary driver. The others are gene Therapy Development and foundation Model Transition.
Who are Holostem's main competitors?
Direct peers on record are Aurion Biotech, jCyte and GenSight Biologics. Broad incumbents are Regenxbio, Chiesi Farmaceutici and Iovance Biotherapeutics. Kala Pharmaceuticals is listed as an others. Emerging players are Capricor Therapeutics, Adaptimmune and Lineage Cell Therapeutics.
Does Holostem have an API?
No public API is recorded for Holostem.
What industry is Holostem in?
Holostem's product category is Regenerative Medicine. Its primary akta.pro industry code is HLAAABAE, Stem Cell Therapies (MSC/iPSC/HSC-derived). Its NAICS code is 325414 and its SIC code is 2836.